In an in vivo model, using 3‐nitropropionic acid (3‐NP) to induce Huntington's disease, CBG (10 mg·kg−1 per day i.p.)significantly attenuated the up‐regulation of COX‐2, iNOS, IL‐6, and TNF‐α (Valdeolivas et al., 2015). This evidence concerns the gene TNF and juvenile Huntington disease.